Non-Viral Drug Delivery Systems Market Analysis With Focus On Growth Potential And Future Outlook
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Non-Viral Drug Delivery Systems Market From 2026 To 2030?
The market size for non-viral drug delivery systems has experienced rapid expansion in recent years. This market is projected to grow from $9.84 billion in 2025 to $11.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.4%. The historical growth can be attributed to factors such as a reliance on viral delivery methods, limited awareness of non-viral techniques, the development of emerging biologics, the establishment of initial regulatory frameworks for drug delivery, and an early academic research focus on nanoparticles.
The non-viral drug delivery systems market size is projected to experience significant expansion in the upcoming years. It is expected to reach $19.07 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.1%. This market’s growth during the forecast period is attributable to breakthroughs in polymer-based carriers, the increasing prevalence of RNA and DNA therapeutics, heightened investment in personalized medicine, the growth of contract development and manufacturing organizations (CDMOs), and more collaborations between pharmaceutical firms and academic institutions. Dominant trends anticipated in this period encompass the growing acceptance of non-viral delivery platforms for targeted therapies, increased utilization of nanoparticles and liposome-based carriers, a focus on mitigating immune responses and improving safety, the advancement of personalized medicine and targeted therapeutics, and the widening scope of CDMOs and academic research partnerships.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24628&type=smp
Which Primary Drivers Are Impacting The Non-Viral Drug Delivery Systems Market Growth?
The expanding need for personalized medicines is projected to fuel the advancement of the non-viral drug delivery systems market moving forward. Personalized medicine refers to a medical methodology that tailors treatment to an individual’s distinct genetic makeup, lifestyle, and environment. The demand for personalized medicine is escalating because it facilitates more effective treatments by specifically targeting the root causes of disease in each patient. Non-viral systems play a crucial role in personalized medicine by safely conveying drugs or genes to cells, minimizing risks, and improving the precision of treatment. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA gave approval to 16 new personalized therapies for patients with rare diseases, which was an increase from 6 approvals in 2022. Hence, the increasing demand for personalized medicines is a primary driver for the growth of the non-viral drug delivery systems market.
Which Segments Define The Non-Viral Drug Delivery Systems Market Segment Structure?
The non-viral drug delivery systems market covered in this report is segmented –
1) By Type Of Molecule Delivered: Biologics, Small Molecules
2) By Type Of Biologics Delivered: Ribonucleic Acid (RNA), Deoxyribonucleic Acid (DNA), Proteins or Peptides, Antibodies
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Development And Manufacturing Organizations (CDMOs), Hospitals And Clinics
Subsegments:
1) By Biologics: Peptides, Proteins, Monoclonal Antibodies, RNA-based Therapeutics, DNA-based Therapies
2) By Small Molecules: Chemotherapeutics, Anti-inflammatories, Antivirals, Antibiotics, Hormonal Drugs
Which Trends Are Shaping Growth In The Non-Viral Drug Delivery Systems Market?
Leading companies within the non-viral drug delivery system market are directing their efforts towards advanced technologies, specifically pre-optimized ionizable lipid mix systems, to streamline the development and delivery processes for RNA-based therapeutics. A pre-optimized ionizable lipid mix system functions as a formulation technology adept at efficiently encapsulating RNA molecules into lipid nanoparticles, thereby ensuring high stability, protecting the payload, and facilitating targeted delivery for gene-based drug applications. As an illustration, in September 2024, Cytiva, a US-based biotechnology company, unveiled an RNA delivery LNP kit compatible with its NanoAssemblr Ignite and Ignite+ platforms. This particular system incorporates a ready-to-use ionizable lipid mix, which allows for quick screening of RNA payloads and validation of effective delivery, especially pertinent in the context of developing infectious disease vaccines. Furthermore, it integrates smoothly with automated microfluidic platforms, supports scalable manufacturing via GMP-grade components, and provides protocols along with proof-of-concept data to guide users from the initial stages of discovery through to clinical evaluation.
Who Are The Established Players Within The Non-Viral Drug Delivery Systems Market?
Major companies operating in the non-viral drug delivery systems market are Evonik Industries AG, Cytiva, Arcturus Therapeutics Holdings Inc., CureVac N.V., PolyPid Ltd, Ethris GmbH, Entos Pharmaceuticals Inc., Liquidia Technologies Inc., ReCode Therapeutics Inc., Enable Injections Inc., GenEdit Inc., N4 Pharma Plc, Hopewell Therapeutics Inc., Tiba Biotech LLC, Vesigen Therapeutics Inc., Carmine Therapeutics Inc., Evox Therapeutics Ltd, InnoCore Pharmaceuticals BV, Nanomerics Ltd, DelSiTech Ltd, Curapath Inc.
Get The Full Non-Viral Drug Delivery Systems Market Report:
Which Region Holds The Highest Market Share In The Non-Viral Drug Delivery Systems Market?
North America was the largest region in the non-viral drug delivery systems market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral drug delivery systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Viral Drug Delivery Systems Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Viral Drug Delivery Systems Market 2026, By The Business Research Company
Advanced Drug Delivery Systems Market Report 2026
Electronic Drug Delivery Systems Market Report 2026
Pharmaceutical Drug Delivery Market Report 2026
https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
